Dr. James Lederer will be presenting a talk entitled ‘SUPLEXA Therapeutic cells – a highly differentiated non-engineered and tumor agnostic autologous cellular therapy in Phase 1 Testing’ at the Cell Therapy Durability Response Summit in Boston on the afternoon August 23rd at the Hilton Boston Back Bay. He is also participating in a panel discussion afterwards entitled ‘Will moving beyond CAR-αβT and CAR-NK overcome the hurdles to solid tumor cell therapy?’
https://www.celltherapydurability.com/events/cell-therapy-durability-response-summit-usa-2022